High-dose therapy with fluconazole ≤800 mg day-1

Mycoses

Volumn 40, Issue 7-8, 1997, Pages 267-277

  Duswald, K H ^a   Penk, A ^b   Pittrow, L ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b PFIZER INC   (United States)

Author keywords

Antimycotic chemotherapy; Candidaemia; Cryptococcal meningitis; Endemic mycoses; Fluconazole; High dose therapy 800 mg day 1; Non neutropenic patients; Oropharyngeal candidosis

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE;

CANDIDA; CANDIDIASIS; COCCIDIOIDES IMMITIS; CRYPTOCOCCUS NEOFORMANS; DRUG SAFETY; FUNGAL MENINGITIS; HUMAN; MYCOSIS; PRIORITY JOURNAL; REVIEW;

EID: 0031440051     PISSN: 09337407     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1439-0507.1997.tb00231.x     Document Type: Review

References (85)

1. Pfaller, M. & Wenzel, R. (1992) Impact of the changing epidemiology of fungal infections in the 1990s. Em J Clin Microbiol Infect Dis 11, 287-291.
2. Jarvis, W. R. & Martone, W. J. (1991) Predominant pathogens in hospital infections. J Antimicrob Chemother 28 (Suppl. A), 15-19.
3. Beck-Sague, C. & Jarvis, W. R. (1993) Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J Infect Dis 167, 1247-1251.
4. Banerjee, S. N., Emori, T. G., Culver, D. H., Gaynes, R. R., Jarvis, W. R. & Horan, T. (1991) Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. Am J Med 89 (Suppl. 3B), 86-89.
5. Wey, S. B., Mori, M., Pfaller, M. A., Woolson, R. F. & Wenzel, R. P. (1988) Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med 148, 2642-2645.
6. Wey, S. B., Mori, M., Pfaller, M. A., Woolson, R. F. & Wenzel, R. P. (1989) Risk factors for hospital-acquired candidemia: a matched case-control study. Arch Intern Med 149, 2349-2353.
7. Frazer, V. J., Jones, M. & Dunkel, J. et al. (1992) Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 15, 414-421.
8. Walsh, T. F. & Pizzo, P. A. (1988) Nosocomial fungal infections: a classification for hospital-acquired infections and mycoses arising from endogenous flora or reactivation. Ann Rev Microbiol 42, 517-545.
9. Wenzel, R. (1995) Nosocomial Candidemia: Risk Factors and Attributable Mortality. Clin Infect Dis 20, 1531-1534.
10. Graninger, W., Presteril, E., Schneeweiss, B., Teleky, B. & Georgopoulos, A. (1993) Treatment of Candida albicans fungemia with fluconazole. J Infect 26, 133-146.
11. Graybill, J. R. (1994) Is there a correlation between serum antifungal drug concentration and clinical outcome? J Infect 28 (Suppl. 1), 17-24.
12. Anaissie, E. J., Kontoiannis, D. P., Huls, C., Vartivarian, S. E., Karl, C., Prince, R. A., Bosso, J. & Bodey, G. P. (1995) Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mould infections. J Infect Dis 172, 599-602.
13. National Committee for Clinical Laboratory Standards. Reference method for broth dilution anti-fungal susceptibility testing of yeasts; proposed standard M27-T (1995) In: National Committee for Clinical Laboratory Standards. Wayne, Philadelphia.
14. Rex, J. H., Pfaller, M. A., Galgiani, J. N., Bartlett, M. S., Espinel-Ingroff, A., Ghannoum, M. A., Lancaster, M., Odds, F. C., Rinaldi, M. G., Walsh, T. J., Barry, A. L. for the Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards (1997) Development of Interpretive Breakpoints for Antifungal Susceptibility Testing: Conceptual Framework and Analysis of In Vitro-In Vivo Correlation Data for fluconazole, itraconazole, and Candida Infections. Clin Infect Dis 24, 235-247.
15. NCCLS Subcommittee on Antifungal Susceptibility Tests: Summary minutes on the Open meeting held June 1, 1996 in Reston VA (unpublished).
16. Pittrow, L. & Penk, A. (1996) Plasma-und Gewebekonzentrationen von Fluconazol: Diskussion der Breakpoint-Problematik. Mycoses 39 (Suppl. 2), 58-65.
17. Phillips, P., Shafran, S., Garber, G., Rotstein, C., Smaill, F., Williams, K., Singer, J., Ioannou, S. and the Canadian Candidemia Study Group (1995) Fluconazole versus Amphotericin B for Candidemia in Nonneutropenic Patients: A Multicenter Randomized Trial. Poster LM20, 35. ICAAC, San Francisco.
18. Nguyen, M. H., Peacock, J. E., Tanner, D. C., Morris, A. J., Nguyen, M. L., Snydman, D. R., Wagener, M. M. & Yu, V. L. (1995) Therapeutic Approaches in Patients with Candidemia. Arch Intern Med 155, 2429-2435.
19. He, X., Tiballi, R. N., Zarins, L. T., Bradley, S. K., Sangeorzan, J. A., Kauffman, C. A. (1994) Azole Resistance in Oropharyngeal Candida albicans Strains Isolated from Patients Infected with Human Immunodeficiency Virus. Antimicrob Agents Chemother 38, 2495-2497.
20. Sangeorzan, J. A., Bradley, S. F., He, X., Zarins, L. T., Ridenour, G. L., Tiballi, R. N. & Kauffman, C. A. (1994) Epidemiology of Oral Candidiasis in HIV-Infected Patients: Colonization, Infection, Treatment, and Emergence of Fluconazole Resistance. Am J Med 97, 339-346.
21. Pagani, J. L., Chave, J. P., Iten, A., Durussel, C., Bille, J. & Glauser, M. P. (1996) Traitement par doses croissantes de la candidose oropharyngée resistant au fluconazole. Schweiz Med Wochenschr 126 (Suppl. 74/II), 495.
22. Redding, S., Smith, J., Farinacci, G., Rinaldi, M., Fothergill, A., Rhine-Chalberg, J. & Pfaller, M. (1994) Resistance of Candida albicans to Fluconazole During Treatment of Oropharyngeal Candidiasis in a Patient with AIDS: Documentation by In Vitro Susceptibility Testing and DNA Subtype Analysis. Clin Inject Dis 18, 240-242.
23. Silling, G., Fegeler, W., Roos, N., Schomaker, R., Essink, M. & Büchner, T. (1997) Early Empiric Treatment of Infections in Neutropenic Patients Comparing Fluconazole with Amphotericin B/5-Flucytosine. Acute Leukemias VI: Prognostic Factors and Treatment Strategies, Büchner et al. (eds) Springer-Verlag Berlin Heidelberg pp. 489-493.
24. Kunzelmann, V., Tietz, H. J., Roßner, D., Czaika, V., Hopp, M., Schmalreck, A. & Sterry, W. (1996) Voraussetzungen für eine effektive Therapie chronisch rezidivierender Vaginalcandidosen. Mycoses 39 (Suppl. 1), 65-72.
25. McLachlan, A. J., Tett, S. E. (1996) Pharmarokinetics of fluconazole in people with HIV infection: a population analysis. Br J Clin Pharmacol 41, 291-298.
26. Anaissie, E. J., Darouiche, R. O., Ahi-Said, D., Uzun, O., Mera, J., Gentry, L. O., Williams, T., Kontoyiannis, D. P., Karl, C. I. & Bodey, G. P. (1996) Management of Invasive Candidal Infections: Results of a Prospective, Randomized, Multicenter Study of Fluconazole Versus Amphotericin B and Review of the Literature. Clin Infect Dis 23, 964-972.
27. British Society for Antimicrobial Chemotherapy Working Party (1994) Management of deep Candida infection in surgical and intensive care unit patients. Intensive Care Med 20, 522-528.
28. Anaissie, E. & Solomkin, J. S. (1994) Algorithm and Explanation: Approach to the Surgical Patient at Risk for Candidiasis. Infection IX, Chapter 10: Fungal Infection, Scientific American, Inc.
29. Abi-Said, D., Vartivarian, S. E., Bodey, G. P. & Anaissie, E. (1995) Hematogenous Candidiasis: A review of therapeutic studies of fluconazole and amphotericin B and recommendations for management. J Mycol Med 5, 217-224.
30. Meyer, R. D. (1994) Treatment of Fungal Infections in Patients with HIV-Infection or AIDS. Zbl. Bakt. 281, 1-7.
31. Meyer, P., Adam, D., Hiddemann, W., Link, H., Maschmeyer, G. & Helmerking, M. (1992) Interventionstherapic von Infektionen und Fieber unklarer Genese bei neutropenischen Patienten mit malignen hämatologischen Grunderkrankungen. Zeitschr Antimicrob Antineoplast Chemother 10, 1-27.
32. Johnson, E. M. & Warnock, D. W. (1995) Azole drug resistance in yeasts. J Antimicrob Chemother 36, 751-755.
33. Warnock, D. W. (1996) Azole resistance in yeasts. J Infect 32, 93.
34. Presterl, E., Laßnigg, A., Willinger, B. & Graninger, W. (1996) Candida-Infektionen in der Intensivmedizin. Anaesthesist 45, 195-210.
35. Berry, A. J., Rinaldi, M. G. & Graybill, J. R. (1992) Use of High-Dose Fluconazole as Salvage Therapy for Cryptococcal Meningitis in Patients with AIDS. Antimicrob Agents Chemother 36, 690-692.
36. Haubrich, R. H., Haghighat, D., Bozzette, S. A., Tilles, J., McCutchan, J. A. and the California Collaborative Treatment Group (1994) High-Dose Fluconazole for Treatment of Cryptococcal Disease in Patients with Human Immunodeficiency Virus Infection. J Infect Dis 170, 238-242.
37. Menichetti, F., Fiorio, M., Tosti, A., Gatti, G., Pasticci, M. B., Miletich, F., Marroni, M., Bassetti, D. & Pauluzzi, S. (1996) High-Dose Fluconazole Therapy for Cryptococcal Meningitis in Patients with AIDS. Clin Infect Dis 22, 838-40.
38. Milefchik, E., Leal, M., Haubrich, R. H., Haghighat, D., Bozzette, S. A. & Larsen, R. A. High Dose Fluconazole with and without Flucytosine for AIDS Associated Cryptococcal Meningitis. WS-B12-5, 9. International Conference on AIDS, June 7-11, 1993, Berlin, Germany.
39. Larsen, R. A. Combination Therapy for Cryptococcosis and Speculations for Future Therapy. V3, Conference Cryptococcus & Cryptococcosis, September 22-26, 1996, Paris, France.
40. Paugam, A., Dupouy-Camet, J., Blanche, P., Gangneux, J. P., Tourte-Schaefer, C. & Sicard, D. (1994) Increased Fluconazole Resistance of Cryptococcus neoformans isolated from a Patient with AIDS and Recurrent Meningitis. Clin Inject Dis 19, 975-976.
41. Sitbon, O., Fourme, T., Bourre, P., Du Pasquier, L. & Salmeron, S. (1993) Successful treatment of disseminated cryptococcosis with high-dose oral fluconazole. AIDS 7, 1685-1687.
42. Tomberlin, M. G., Baingana, G., Grant, R., Mbidde, E. K., Sande, M. A. Fluconazole with and without Flucytosine for AIDS-Related Cryptococcal Meningitis in Uganda. Abstr. M71, 34. ICAAC, 1994, Orlando, USA.
43. Marriott, D. J. E. Long-term high dose fluconazole as salvage therapy for AIDS related cryptococcal meningitis: clinical and autopsy findings. Cryptococcosis Meeting, 1993, Milano, Italy.
44. Pappas, P. G., Hamill, R. J., Kauffman, C. A., Bradsher, R. W., McKinsey, D. S., Cloud, G. W. & Dismukes, W. E. (1996) Treatment of Cryptococcal Meningitis in Non-HIV Infected Patients - A Randomized Comparative Trial. Clin Infect Dis 23, 873.
45. Just-Nübling, G. (1994) Die Therapie der Candidose und Cryptococcose bei AIDS. Mycoses 37 (Suppl. 2), 56-63.
46. Larsen, R. A., Bozzette, S. A. & Jones, B. E. (1994) Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 19, 741-745.
47. Bozzette, S. A., Larsen, R. A., Chiu, J., Leal, M. A., Jacobsen, J. & Rothman, P. (1991) A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. N Engl J Med 324, 580-584.
48. Powderly, W. G., Saag, M. S. & Cloud, G. A. (1992) A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. N Engl J Med 326, 793-798.
49. Villanueva, M. S. & Quagliarello, V. J. (1996) Prevention and Treatment of Cryptococcal Meningitis in Patients with AIDS. CNS Drugs 4, 246-256.
50. McKinsey, D. S., Kauffman, C. A., Pappas, P. G., Cloud, G. A., Girard, W. M., Sharkey, P. K., Hamill, R. J., Thomas, C. J., Dismukes, W. E. and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (1996) Fluconazole Therapy for Histoplasmosis. Clin Infect Dis 23, 996-1001.
51. Sharkey-Mathis, P. K., Velez, J., Fetchick, R. & Graybill, J. R. (1993) Histoplasmosis in the Acquired Immunodeficiency Syndrome (AIDS): Treatment with Itraconazole and Fluconazole. J Acquired Immune Deficiency Syndrome 6, 809-819.
52. Wheat, L., Mawhinney, S., Hafner, R., McKinsey, D. Fluconazole Treatment for Histoplasmosis in AIDS: Prospective Multicenter Non-comparative Trial. Abstr. 1233, 34. ICAAC, 1994, Orlando, USA.
53. Pappas, P. G., Kauffman, C. A., Perfect, J. R., Johnson, P. C., McKinsey, D. S., Bamberger, D. M., Hamill, R., Sharkey, P. K., Chapman, S. W. & Sobel, J. D. (1995) Alopecia Associated with Fluconazole Therapy. Ann Intern Med 123, 354-357.
54. Kauffman, C. A., Pappas, P. G., McKinsey, D. S., Greenfield, R. A., Perfect, J. R., Cloud, G. A., Thomas, C. J., Dismukes, W. L. and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (1996) Treatment of Lymphocutaneous and Visceral Sporotrichosis with Fluconazole. Clin Infect Dis 22, 46-50.
55. Wheat, J. (1995) Endemic Mycoses in AIDS: A Clinical Review. Clin Microb Rev 8, 146-159.
56. Penk, A. & Pittrow, L. (1997) Seltene Mykosen in der operativen Medizin. In: Mykosen in der operativen Medizin (Hrsg.: Kujath, P). Thieme, Stuttgart-New York (to be published).
57. Anaissie, E. J., Kontoyiannis, D., Huls, C., Prine, R., Bosso, J. A. & Bodey, G. P. Efficacy, Safely and Pharmacokinetics of High Dose Fluconazole in Patients with Fungal Infections. Abstr. 626, 32. ICAAC, 1992, Anaheim, USA.
58. Koszyca, B., Ellis, D., Toogood, I. & Byard, R. W. Fluconazole in the treatment of pulmonary zygomycosis. Mycoses 38, 277-280.
59. Diaz, M., Negroni, R., Montero-Gei, K., Castro, L. G. M., Sampaio, S. A. P., Borelli, D., Restrepo, A., Franco, L., Bran, J. L., Arathoon, E. G. & Stevens, D. A. (1992) A Pan-American 5-Year Study of Fluconazole Therapy for Deep Mycoses in the Immunocompctent Host. Clin Infect Dis 14 (Suppl. 1), 568-576.
60. Sundar, S., Singh, V. P., Agraval, N. K., Gibbs, D. L., Murray, H. W. (1996) Treatment of kala-azar with oral fluconazole. Lancet 348, 614.
61. Pittrow, L. & Penk, A. (1997) Plasma and Tissue Concentrations of Fluconazole and their Correlation to Breakpoints. Mycoses 40, 25-32.
62. Pittrow, L. & Penk, A. (1997) Voraussetzungen für eine effektive antimykotische Therapie bei nichtneutropenischen Patienten. In: Mykosen in der operativen Medizin (Hrsg.: Kujath, P). Thieme, Stuttgart-New York (to be published).
63. Ansari, A. M., Gould, I. M. & Douglas, J. G. (1990) High dose oral fluconazole for oropharyngeal candidosis in AIDS. JAC 25, 720-721.
64. Hood, S. & Denning, D. W. (1996) Treatment of fungal infection in AIDS. JAC 37 (Suppl. B), 71-85.
65. Mitchell, T. G., Perfect, J. R. (1995) Cryptococcosis in the Era of AIDS - 100 Years after the Discovery of Ctyptococcm neoformans: Clin Microbiol Rev 8, 515-548.
66. Einstein, H. E. & Johnson, R. H. (1993) Coccidioidomycosis: New Aspects of Epidemiology and Therapy. Clin Infect Dis 16: 349-356.
67. Galgiani, J. N., Catanzaro, A., Cloud, G. A., Higgs, J., Friedman, B. A., Larsen, R. A. & Graybill, J. R. (1993) Fluconazole Therapy for Coccidioidal Meningitis. Ann Intern Med 119, 28-35.
68. Bodey, G., Bueltmann, B., Duguid, W., Gibbs, D., Hanak, H., Hotchi, M., Mall, G., Martino, P., Meunier, F., Milliken, S., Naoe, S., Okudaira, M., Scevola, D. & van't Wout, J. (1992) Fungal Infections in Cancer Patients: An International Autopsy Survey. Eur J Clin Microbiol Inject Dis 11, 99-109.
69. Pfaffenbach, B., Donhuijsen, K., Pahnke, J., Bug, R., Adamek, R. J., Wegener, M. & Ricken, D. (1994) Systemische Pilzinfektionen bei hämatologischen Neoplasien. Med Klinik 89, 299-304.
70. Duswald, K. H., Zettl, R., Lederle, J., Penk, A., Pittrow, L. High-Dose Fluconazole ≥800 mg/day in ICU-Patients with Candidiasis. 20th International Congress of Chemotherapy, 1997, Sydney. Abstract 5055.
71. Milefchik, E., Leal, M., Haubrich, R., Bozzette, S., Tilles, J., Leedom, J., McCutchan, J. A., Larsen, R. A. A Phase II Dose Escalation Trial of High Dose Fluconazole With and Without Flucytosine for AIDS Associated Cryptococcal Meningitis. 4th Conference on Retroviruses and Opportunistic Infections, January 22-27, 1997, Washington. Abstract 640.
72. Bernstein, L., Hsu, W. & Schliozberg, J. (1996) High dose fluconazole can be safely administered in AIDS patients with severe oropharyngeal candidiasis: a case report. Ann Allergy 76, 83.
73. Kelly, S. L., Lamb, D. C., Kelly, D. E., Loeffler, J. & Einsele, H. (1996) Resistance to fluconazole and amphotericin B in Candida albicans from AIDS patients. Lancet 349, 1523-1524.
74. Pappas, P. G., Kauffman, C. A., McKinsey, D. S., Bradsher, R. W., Sharkey, P. K., Chapman, S. W., Greenfield, R., Newman, C., Dismukes, W. E. Fluconazole for the Treatment of Blastomycosis, Histoplasmosis and Sporotrichosis. 32nd Annual IDSA Meeting, October 7-9, 1994, Orlando, Abstract 83.
75. Link, H., Maschmeyer, G., Meyer, P., Hiddemann, W., Schrappe, M., Helmerking, M. & Adam, D. Antimicrobial Therapy in Febrile Neutropenic Patients; Results of the Prospective Studies of the Paul-Ehrlich-Society of Chemotherapy. 6th BICON May 2-4, 1996, Leipzig, Abstract 21.
76. Viscoli, C., Castagnola, R., Fioredda, F., Ciravegna, B., Barigione, G. & Terragna, A. (1991) Fluconazole in the Treatment of Candidiasis in Immunocompromised Children. Antimicrob Agents Chemother 35, 365-367.
77. Driessen, M., Cooper, P. A., Wainer, S., Muwazi, F., Hahn, D., Gous, H. & De Villiers, F. P. R. (1996) Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial. Pediatr Infect Dis J 15, 1107-1112.
78. Fasano, C., O'Keeffe, J. & Gibbs, D. (1994) Fluconazole Treatment of Neonates and Infants with Severe Fungal Infections Not Treatable with Conventional Agents. Eur J Clin Microbiol Infect Dis 13, 351-354.
79. Fasano, C., O'Keeffe, J. & Gibbs, D. Fluconazole Treatment of Children with Severe Fungal Infections Not Treatable with Conventional Agents (1994) Eur J Clin Microbiol Infect Dis 13, 344-347.
80. Presterl, K., Graninger, W. and a Multicentre Study Group. Efficacy and Safety of Fluconazole in the Treatment of Systemic Fungal Infections in Pediatric Patients. Eur J Clin Microbiol Infect Dis 13, 347-351.
81. Koletar, S. L., O'Grady, N. P. Treatment of Disseminated Histoplasmosis. IXth International Conference on AIDS, June 6-11, 1993, Berlin, Abstract 1391.
82. Reblin, T., Meyer, A., Albrecht, H. & Greten, H. (1994) Disseminated cryptococcosis in a patient with AIDS. Mycoses 37, 275-279.
83. Powderly, W. G. (1992) Therapy for Cryptococcal Meningitis in Patients with AIDS. Clin Infect Dis 14 (Suppl. 1), S54-S59.
84. Sarosi, G. A., Davies, S. F. (1994) Concise Review for Primary-Care Physicians. Therapy for Fungal Infections. Mayo Clin Proc 69, 1111-1117.
85. Kauffman, C. A. (1996) Role of Axoles in Antifungal Therapy. Clin Infect Dis 22 (Suppl. 2), S148-S153.